PMS and PMDD: premenstrual syndrome in AU general practice

Premenstrual syndrome and its severe form, premenstrual dysphoric disorder, are among the most underdiagnosed and under-managed conditions in Australian general practice. Up to 80% of menstruating women experience some cyclical symptoms. Around 20–30% have symptoms severe enough to affect daily functioning. And 3–8% meet criteria for PMDD — a DSM-5-defined clinical syndrome that causes significant impairment, elevated suicidality, and is often mistaken for depression or anxiety because its cyclical pattern is not asked about in routine consultations.

The core clinical insight that unlocks diagnosis is the timing. Symptoms occur in the luteal phase — typically the final week to ten days before menstruation — and remit within a few days of the period starting. A symptom-free interval in the week following menses is an essential diagnostic feature. When this pattern is present, the working diagnosis shifts from general mood disorder toward premenstrual syndrome or PMDD, and the management approach changes accordingly.

Jean Hailes for Women’s Health is Australia’s leading authority on premenstrual conditions and provides evidence-aligned patient and clinician resources for PMS and PMDD management in general practice.

A. Core clinical — the AU general-practice framework

Definitions

Premenstrual syndrome (PMS): cyclical physical and emotional symptoms in the luteal phase that resolve with menstruation, with a symptom-free follicular phase. Severity ranges from mild to moderate-severe. PMS is not a DSM-5 diagnosis but is the most common premenstrual presentation.

Premenstrual dysphoric disorder (PMDD): a DSM-5-TR defined clinical syndrome requiring:

• Five or more symptoms in the final week before menses in most cycles in the past year, with at least one being affective (marked mood lability, marked irritability or anger, markedly depressed mood or hopelessness, marked anxiety or tension)
• The symptom cluster causes clinically significant distress or impairment
• Symptoms remit within a few days of menses onset and are minimal or absent in the week following menses
• Confirmed by prospective daily ratings over at least two symptomatic cycles (provisional diagnosis if diary not yet completed)

Premenstrual exacerbation (PME): an underlying condition (depression, anxiety, ADHD, autism, migraine, irritable bowel syndrome, asthma) that worsens premenstrually. PME and PMDD require different management approaches — treat the underlying condition in PME.

Epidemiology and risks

PMS affects up to 80% of menstruating women to some degree; moderate-to-severe PMS affects 20–30%. PMDD affects approximately 3–8%, with onset typically in the late teens to mid-30s. PMDD often worsens during the perimenopausal transition.

Suicidality is significantly elevated in PMDD. Research cited by the International Association for Premenstrual Disorders (IAPMD) describes lifetime suicidal ideation in approximately 30% and lifetime suicide attempt in approximately 15% of people with PMDD. Explicit suicide risk assessment at every consultation is mandatory.

Strong associations exist with: childhood adversity and trauma history, personal or family history of depression or anxiety, PTSD, and perimenopausal hormonal transition.

Pathophysiology

PMDD does not arise from abnormal hormone levels — luteal hormone profiles are typically normal. The mechanism is abnormal central nervous system sensitivity to the normal cyclical fluctuations of oestrogen and progesterone, particularly to allopregnanolone (a neurosteroid progesterone metabolite that modulates GABA-A receptors). This explains why SSRIs work rapidly in PMDD — they act on the allopregnanolone–GABA-A pathway rather than through the slow neuroplastic mechanism responsible for their antidepressant effect.

Suppressing ovulation with combined oral contraceptives or GnRH agonists markedly reduces the cyclical hormone fluctuation, with substantial symptom reduction in most patients — this is the basis for both hormonal treatments.

Diagnosis: the prospective symptom diary

The DSM-5 requirement for prospective daily symptom tracking over at least two cycles is clinically essential. Retrospective recall consistently over-estimates symptom severity and misses the follicular-phase symptom-free window that distinguishes PMDD from chronic depression.

Daily Record of Severity of Problems (DRSP): a 24-item validated instrument that rates each symptom on a six-point severity scale. Provide the DRSP or an equivalent diary at the first consultation and review at the next appointment with completed data.

Apps (Clue, Flo, Me v PMDD) can support daily tracking but are not validated diagnostic instruments.

Differential diagnosis

• Major depressive disorder: symptoms persist throughout the cycle without follicular-phase remission
• Generalised anxiety disorder: non-cyclical
• Bipolar disorder: cycling is independent of the menstrual cycle; PMDD can co-occur with bipolar (in ~25%), which requires specialist management
• Hypothyroidism: fatigue and mood change persist throughout cycle; TSH is diagnostic
• Perimenopause: irregular cycles, vasomotor symptoms, FSH variability; PMDD can worsen at this transition
• Endometriosis / chronic pelvic pain: pain pattern predominates

Investigations

No specific blood tests are required for PMS/PMDD diagnosis. Depending on clinical features, consider: TSH if fatigue and weight change predominant; FBC and ferritin for fatigue and anaemia symptoms; HbA1c if metabolic risk; beta-hCG to exclude pregnancy; vitamin D and B12 if deficiency suspected.

B. Evidence appraisal — SSRI and hormonal therapy

SSRIs: first-line pharmacotherapy for PMDD

The Cochrane review of SSRIs for PMS/PMDD (Marjoribanks 2013) found a response rate of 50–70% improvement in PMDD symptoms with SSRIs, with consistent evidence across continuous and luteal-phase administration.

PBS-available SSRIs for PMDD:

• Sertraline 50–150 mg/day (General Schedule — preferred first choice)
• Paroxetine 10–20 mg/day (General Schedule)
• Fluoxetine 20 mg/day (General Schedule — long half-life makes luteal-phase dosing more complex)
• Escitalopram 10–20 mg/day (General Schedule)
• Citalopram 20 mg/day (General Schedule — QT caution at higher doses)

Dosing strategies:

• Continuous: daily dosing, most evidence, preferred for affective, cognitive, and physical symptoms
• Luteal-phase only: SSRI taken from approximately cycle day 14 through day 28 (onset of menses) — comparable efficacy in many trials, reduces cumulative exposure, preferred when fertility planning
• Symptom-onset dosing: emerging evidence; start at first symptom emergence each cycle

Onset of benefit: rapid — often 24 to 48 hours for PMDD, compared with four to six weeks for major depressive disorder. This rapid response is a distinguishing clinical feature.

Monitoring: assess suicide risk at initiation and first review, especially in the first two to four weeks (black-box warning for patients under 25).

Drospirenone-containing COC

The 24/4 drospirenone/ethinyloestradiol regimen (Yaz, Yasmin Yaz LD in Australia) has large trial evidence and regulatory approval for PMDD in Australia and the USA per RANZCOG and ACOG Clinical Practice Guideline No. 7 (2023). Drospirenone’s anti-mineralocorticoid and anti-androgenic properties address bloating and acne alongside the affective symptoms. The 24/4 regimen shortens the hormone-free interval that triggers symptom recurrence.

Note: Drospirenone COCs are not PBS-listed in Australia. Private prescription cost is approximately AUD 80–100 per month. Consider PBS-listed SSRIs as a first-line pharmacological option when cost is a barrier.

Other COCs are less targeted for PMDD; evidence for older levonorgestrel-based formulations is limited.

Contraindications to COC: apply standard COC contraindications per WHO Medical Eligibility Criteria — personal or family history of VTE, migraine with aura, hypertension, age ≥35 with smoking, severe liver disease, oestrogen-sensitive malignancy.

GnRH agonists with add-back HRT

For severe refractory PMDD not responding to SSRIs and drospirenone COC, GnRH agonists (leuprorelin, goserelin) suppress ovulation and eliminate cyclical symptoms in 70–80% of patients per the RCOG Green-top Guideline No. 48. Add-back oestrogen plus progestogen HRT is essential after the first three months to prevent oestrogen deficiency complications including osteoporosis.

GnRH agonist therapy is specialist-led. It serves as both treatment and a diagnostic test — response confirms PMDD rather than an underlying mood disorder.

C. CBT, lifestyle, and adjuncts

Cognitive behavioural therapy

CBT is effective for PMDD — multiple RCTs show reductions in symptom severity and functional impairment. Access via the Better Access Mental Health Treatment Plan (MHCP item 2715/2717) and ten individual psychology sessions per calendar year under Medicare. Mindfulness-based therapies and acceptance and commitment therapy are also used.

The MHCP makes CBT accessible for patients at subsidised cost. Jean Hailes for Women’s Health offers online courses and group programs for PMS/PMDD self-management.

Lifestyle foundations

For all severity levels:

• Aerobic exercise ≥150 minutes per week — mood and physical symptom benefit
• Sleep hygiene — consistent schedule, ≥7 hours per night reduces mood lability
• Reduce caffeine — worsens anxiety, breast tenderness, and sleep disturbance
• Alcohol moderation — alcohol worsens mood and depression risk in PMDD
• Smoking cessation — strongly associated with severe PMS; address routinely

Evidence-supported adjuncts

• Calcium 1000–1200 mg/day — RCT evidence (Thys-Jacobs); reduces PMS symptoms by approximately 50%
• Magnesium glycinate/citrate 200–400 mg/day — small RCTs; physical symptom benefit
• Vitamin B6 (pyridoxine) 50–100 mg/day — meta-analysis evidence; do not exceed 100 mg/day (peripheral neuropathy risk at higher doses)
• Chasteberry (Vitex agnus-castus) standardised extract 4–40 mg/day — Cochrane signal positive; dopaminergic mechanism suppressing prolactin; avoid in pregnancy and concurrent hormone therapy

D. Australian operations

MBS billing

• Items 23, 36, 44 — GP consultation for initial assessment, diary review, follow-up
• Item 2715 / 2717 — MHCP preparation for CBT access
• Item 2712 — MHCP review
• Items 80000–80020 — Better Access individual psychology sessions
• Item 39666 — IUD insertion if LNG-IUD used as contraception adjunct
• Item 10954 — dietitian referral under GPCCMP for nutritional support
• Item 715 — ATSI Health Assessment as entry point for mental health screening

PBS prescribing

PBS General Schedule: sertraline, fluoxetine, paroxetine, escitalopram, citalopram. Not PBS-listed: drospirenone COCs (Yaz, Yasmin Yaz LD) — private prescription only. PBS Authority: leuprorelin (Authority for endometriosis, off-label for severe PMDD). OTC (not PBS): calcium, magnesium, vitamin B6, chasteberry.

Check PBS Online for current schedules and conditions.

Cultural safety

For First Nations women: a yarning approach; single-sex consultations where preferred; ATSI Health Assessment as gateway; 13YARN (13 92 76) crisis line. For CALD patients: TIS National interpreter service; consider cultural understanding of menstruation and stigma around mental health. For LGBTQI+ patients: gender-affirming language; people with ovaries who menstruate can have PMDD regardless of gender identity.

Documentation

Document: DSM-5-TR PMDD criteria with diary evidence; suicide risk assessment; shared decision-making conversation about SSRI versus COC versus combination; referral and follow-up plan.

E. Special populations

Adolescents (≥16). Menstrual cycles may be irregular in the first two years — exercise caution in diagnosing PMDD until cycles establish. Lifestyle and CBT first-line. SSRIs used judiciously with close suicidality monitoring (black-box warning, close review in the first four weeks).

Perimenopause. PMDD frequently worsens as cycles become irregular and hormone fluctuations intensify. This is a transition period that often requires both continued PMDD management and initiation of menopause management — HRT and SSRI can be combined. See the separate article on perimenopause for the parallel hormonal management pathway.

Trying to conceive or pregnant. Luteal-phase SSRI dosing minimises in utero exposure if pregnancy occurs in the early cycle before awareness of conception. Sertraline is generally preferred if SSRI is continued in pregnancy. PMDD by definition does not occur during pregnancy (no cycling). Manage any mood symptoms during pregnancy under the perinatal mental health framework.

Transgender and non-binary people. People with ovaries who menstruate — including those on testosterone who have partial or full cycle suppression — can experience PMDD if ovulation is occurring. Use affirming language and individualise management to cycle pattern and gender identity.

When to escalate

Escalate to gynaecology (RANZCOG specialist) when:

• GnRH agonist therapy is being considered for severe refractory PMDD
• Comorbid endometriosis or chronic pelvic pain requires surgical evaluation
• Surgical management (BSO + hysterectomy) is under consideration

Escalate to psychiatry when:

• Bipolar disorder is suspected — antidepressant monotherapy may destabilise bipolar mood
• Comorbid severe depression, severe anxiety, PTSD, eating disorder, or personality disorder requires specialist management
• PMDD is treatment-resistant after adequate SSRI trial and drospirenone COC

Escalate urgently when:

• Suicidal ideation with plan or intent — emergency department and acute mental health team

What this article is and is not

This is general health information drawn from current Australian and international guidelines — Jean Hailes for Women’s Health, RANZCOG, eTG Obstetrics and Gynaecology, RCOG Green-top 48, and ACOG CPG No. 7 (2023). It is not personal medical advice and does not create a doctor–patient relationship. Individual management — including choice of SSRI, dosing strategy, and hormonal treatment — requires assessment by the treating GP.

For Australian consumer information: Jean Hailes for Women’s Health, HealthDirect — PMS, Beyond Blue. For crisis support: Lifeline 13 11 14, Beyond Blue 1300 22 4636.

---

Sources cited

1. Jean Hailes for Women’s Health — PMS and PMDD
2. RANZCOG — Premenstrual syndrome and PMDD
3. Therapeutic Guidelines (eTG) — Obstetrics and Gynaecology
4. RACGP
5. RCOG Green-top Guideline No. 48
6. ACOG Clinical Practice Guideline No. 7 (2023)
7. Cochrane — SSRIs for PMS/PMDD (Marjoribanks 2013)
8. Beyond Blue
9. HealthDirect — PMS
10. IAPMD
11. TGA
12. PBS